146 related articles for article (PubMed ID: 35390515)
1. Digital PCR for Minimal Residual Disease Quantitation Using Immunoglobulin/T-Cell Receptor Gene Rearrangements in Acute Lymphoblastic Leukemia: A Proposed Analytic Algorithm.
Lu Y; Li Z; Lim EH; Huan PT; Kham SKY; Yeoh AE
J Mol Diagn; 2022 Jun; 24(6):655-665. PubMed ID: 35390515
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
3. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
4. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
6. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol.
Svaton M; Skotnicova A; Reznickova L; Rennerova A; Valova T; Kotrova M; van der Velden VHJ; Brüggemann M; Darzentas N; Langerak AW; Zuna J; Stary J; Trka J; Fronkova E
Blood; 2023 Feb; 141(5):529-533. PubMed ID: 36240445
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
8. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
9. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
10. [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
Zhang YT; Luo ZF; Fang JP; Guo HX; Huang K; Li CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1235-9. PubMed ID: 21129267
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
[TBL] [Abstract][Full Text] [Related]
12. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR.
Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M
Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990
[TBL] [Abstract][Full Text] [Related]
13. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
14. Quality Control for IG /TR Marker Identification and MRD Analysis.
Fronkova E; Svaton M; Trka J
Methods Mol Biol; 2022; 2453():91-99. PubMed ID: 35622322
[TBL] [Abstract][Full Text] [Related]
15. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
[TBL] [Abstract][Full Text] [Related]
16. Real-time quantitative PCR: standardized detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Polymerase chain reaction.
Pine SR; Moy FH; Wiemels JL; Gill RK; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2003 Feb; 25(2):103-8. PubMed ID: 12571459
[TBL] [Abstract][Full Text] [Related]
17. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
18. A New View on Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia using Droplet Digital PCR.
Schwinghammer C; Koopmann J; Chitadze G; Karawajew L; Brüggemann M; Eckert C
J Mol Diagn; 2022 Aug; 24(8):856-866. PubMed ID: 35691569
[TBL] [Abstract][Full Text] [Related]
19. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
20. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
